+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Parkinson's Disease: Global Drug Forecast and Market Analysis to 2026

  • ID: 4605703
  • Report
  • May 2018
  • Region: Global
  • 108 pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • AbbVie
  • Bial
  • Impax Pharmaceuticals
  • MSD
  • Novo Nordisk
  • Roche
  • MORE
Parkinson’s Disease: Global Drug Forecast and Market Analysis to 2026

Summary

Parkinson’s disease (PD) is a chronic and progressive disease, considered an idiopathic form, and accounts for roughly 80% of the cases of Parkinsonism-neurological disorders that lead to movement problems. While the exact cause of Parkinson’s disease is unknown, it may include a number of factors such as aging, environmental factors/exposures, and genetic predispositions.

Current treatments centre on the management of dopamine levels in the brain, with levodopa-based therapies remaining the standard of care in the Parkinson’s market for the past half century. These therapies provide the best relief of symptoms at a low annual cost of therapy (ACOT), with Sinemet (carbidopa/levodopa) and Madopar (benserazide/levodopa) being the two most popular branded drugs.

The author estimates that drug sales for PD in 2016 were approximately $3.1B across the seven major markets covered in this report. Over the 10-year forecast period, the market is expected to grow to $8.8B at a CAGR of 11.1%. This growth will be driven by the launch of thirteen late-stage pipeline products. The two highest selling drugs are expected to be Roche/Prothena’s PRX-002and Acorda’s CVT-301, which both address some of the unmet needs in the market.

Key Questions Answered
  • What are the key PD treatments in 2016?
  • When will the late stage pipeline products launch, and how will it affect drug sales and the overall PD market in the 7MM?
  • Which unmet needs will remain unaddressed in the forecast period and what opportunities remain for pharmaceutical companies?
Scope
  • Overview of PD, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
  • Annualized PD therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in two patient segments (early and advanced) forecast from 2016 to 2026.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the PD therapeutics market
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for PD therapy. The most promising candidates in Phase III development are profiled.
  • Analysis of the current and future market competition in the global PD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy

The report will enable you to:
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global PD therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global PD therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AbbVie
  • Bial
  • Impax Pharmaceuticals
  • MSD
  • Novo Nordisk
  • Roche
  • MORE
1 Table of Contents

2 Parkinson’s Disease: Executive Summary
2.1 Parkinson’s Market Forecast to Reach $8.8B by 2026
2.2 New Players Expected to Establish Themselves in the Forecast Period as Late-Stage Pipeline Assets Launched
2.3 Disease-Modifying Agents and Late-Stage Complications the Largest Unmet Needs in the PD Market
2.4 Treatments for Late-Stage Complications, Including Dyskinesia and Psychosis, Provide Companies with European and Japanese Opportunity
2.5 Biologics and Reformulations Expected to Drive Growth Pipeline
2.6 What Do Physicians Think?

3 Introduction
3.1 Catalyst
3.2 Related Reports
3.3 Upcoming Related Reports

4 Disease Overview
4.1 Etiology
4.1.1 Overview
4.1.2 Aging
4.1.3 Environmental Factors
4.1.4 Genetic Factors
4.2 Pathophysiology
4.2.1 Overview
4.2.2 Mechanisms of Cell Death

5 Epidemiology
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.3.1 US
5.3.2 5EU
5.3.3 Japan
5.4 Forecast Methodology
5.4.1 Sources
5.4.2 Sources Not Used
5.4.3 Forecast Assumptions and Methods
5.5 Epidemiological Forecast for PD (2016-2026)
5.5.1 Diagnosed Prevalent Cases of PD
5.5.2 Age-Specific Diagnosed Prevalent Cases of PD
5.5.3 Sex-Specific Diagnosed Prevalent Cases of PD
5.5.4 Diagnosed Prevalent Cases of PD by Clinical Staging
5.6 Discussion
5.6.1 Epidemiological Forecast Insight
5.6.2 Limitations of the Analysis
5.6.3 Strengths of the Analysis

6 Disease Management
6.1 Diagnosis and Treatment Overview
6.2 US
6.3 5EU
6.4 Japan

7 Competitive Assessment
7.1 Overview

8 Unmet Needs and Opportunity Assessment
8.1 Overview
8.2 Treatment of Motor Complications - Dyskinesia and OFF Episodes
8.3 Treatment of Non-motor Complications and Dementia
8.4 Neuroprotective/Disease-Modifying Agents
8.5 Improved Drug Formulations

9 Pipeline Assessment
9.1 Overview
9.2 Promising Drugs in Clinical Development

10 Current and Future Players
10.1 Overview
10.2 Trends in Corporate Strategy
10.3 AbbVie
10.4 Roche
10.5 Orion Pharma
10.6 Impax Pharmaceuticals
10.7 Acorda Therapeutics
10.8 Adamas Pharmaceuticals
10.9 UCB
10.10 Kyowa Hakko Kirin
10.11 Other Players

11 Market Outlook
11.1 Global Markets
11.1.1 Forecast
11.1.2 Drivers and Barriers - Global Issues
11.2 US
11.2.1 Forecast
11.2.2 Key Events
11.2.3 Drivers and Barriers
11.3 5EU
11.3.1 Forecast
11.3.2 Key Events
11.3.3 Drivers and Barriers
11.4 Japan
11.4.1 Forecast
11.4.2 Key Events
11.4.3 Drivers and Barriers

12 Appendix
12.1 Bibliography
12.2 Abbreviations
12.3 Methodology
12.3.1 Forecasting Methodology
12.3.2 Diagnosed Patients
12.3.3 Percent Drug-Treated Patients
12.3.4 Drugs Included in Each Therapeutic Class
12.3.5 Launch and Patent Expiry Dates
12.3.6 General Pricing Assumptions
12.3.7 Individual Drug Assumptions
12.3.8 Generic Erosion
12.3.9 Pricing of Pipeline Agents
12.4 Primary Research - KOLs [and Payers] Interviewed for This Report
12.4.1 KOLs
12.4.2 Payers
12.5 Primary Research - Prescriber Survey
12.6 About the Authors
12.6.1 Analyst
12.6.2 Therapy Area Director
12.6.3 Epidemiologist
12.6.4 Managing Epidemiologist
12.6.5 Global Director of Therapy Analysis and Epidemiology
12.6.6 Global Head and EVP of Healthcare Operations and Strategy
12.7 About
12.8 Contact
12.9 Disclaimer

List of Tables
Table 1: Parkinson’s Disease: Key Metrics in the 7MM
Table 2: Risk Factors and Comorbidities for PD
Table 3: 7MM, Diagnosed Prevalent Cases of PD By Clinical Staging, Both Sexes, Ages =18 Years, N, 2016
Table 4: Treatment Guidelines for PD
Table 5: Country Profile - US
Table 6: Country Profile - 5EU
Table 7: Country Profile - Japan
Table 8: Leading Treatments for Parkinson’s Disease, 2016
Table 9: Comparison of Therapeutic Classes in Development for Parkinson’s Disease, 2016-2026
Table 10: AbbVie’s Disease Portfolio Assessment, 2018
Table 11: Roche’s Disease Portfolio Assessment, 2018
Table 12: Orion Pharma’s Disease Portfolio Assessment, 2018
Table 13: Impax Pharmaceuticals’ Disease Portfolio Assessment, 2018
Table 14: Acorda Therapeutics’ Disease Portfolio Assessment, 2018
Table 15: Adamas Pharmaceuticals’ Disease Portfolio Assessment, 2018
Table 16: UCB’s Disease Portfolio Assessment, 2018
Table 17: Kyowa Hakko Kirin’s Disease Portfolio Assessment, 2018
Table 18: Parkinson’s Disease Market - Global Drivers and Barriers, 2016-2026
Table 19: Key Events Impacting Sales for Parkinson’s Disease in the US, 2016-2026
Table 20: Parkinson’s Disease Market - Drivers and Barriers in the US, 2016-2026
Table 21: Key Events Impacting Sales for Parkinson’s Disease in the 5EU, 2016-2026
Table 22: Parkinson’s Disease Market - Drivers and Barriers in the 5EU, 2016-2026
Table 23: Key Events Impacting Sales for Parkinson’s Disease in Japan, 2016-2026
Table 24: Parkinson’s Disease Market - Global Drivers and Barriers in Japan, 2016-2026
Table 25: Key Projected Launch Dates for Parkinson’s disease
Table 26: Key Historical and Projected Patent Expiry Dates for Parkinson’s Disease
Table 27: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures
Figure 1: Global Sales Forecast by Country for Parkinson’s Disease in 2016 and 2026
Figure 2: Analysis of the Company Portfolio Gap in Parkinson’s Disease During the Forecast Period
Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that the author Expects to be Licensed for the Treatment of Parkinson’s Disease During the Forecast Period
Figure 4: 7MM, Age-Standardized Diagnosed Prevalence of PD, Ages =18 Years, 2016
Figure 5: 7MM, Sources Used and Not Used, Diagnosed Prevalent Cases of PD, 2016-2026
Figure 6: 7MM, Sources Used, Diagnosed Prevalent Cases of PD Clinical Staging, 2016-2026
Figure 7: Diagnosed Prevalent Cases of PD, 7MM, Both Sexes, =18 Years, N, 2016
Figure 8: 7MM, Age-Specific Diagnosed Prevalent Cases of PD, Both Sexes, Ages =18 Years, N, 2016
Figure 9: 7MM, Sex-Specific Diagnosed Prevalent Cases of PD, Both Sexes, Ages =18 Years, N, 2016
Figure 10: Treatment Algorithm for Parkinson’s Patients
Figure 11: Unmet Needs and Opportunities in Parkinson’s Disease
Figure 12: Pharmacokinetics of Levodopa
Figure 13: Overview of the Development Pipeline in Parkinson’s Disease
Figure 14: Key Phase II/III Trials for the Promising Pipeline Agents that the author Expects to Be Licensed for PD in the 7MM During the Forecast Period
Figure 15: Competitive Assessment of the Late-Stage Pipeline Agents that the author Expects to Be Licensed for the Treatment of Parkinson’s Disease During the Forecast Period
Figure 16: Analysis of the Company Portfolio Gap in Parkinson’s Disease During the Forecast Period
Figure 17: Global (7MM) Sales Forecast by Country for Parkinson’s Disease in 2016 and 2026
Figure 18: Sales Forecast by Class for Parkinson’s Disease in the US in 2016 and 2026
Figure 19: Country Breakdown for Parkinson’s Disease Sales in the 5EU in 2016 and 2026
Figure 20: Sales Forecast by Class for Parkinson’s Disease in Japan in 2016 and 2026
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Teva
  • Roche
  • Prothena
  • Acorda Therapeutics
  • Voyager Therapeutics
  • Impax Pharmaceuticals
  • UCB
  • AbbVie
  • Novartis
  • Orion Pharmaceuticals
  • Intec Pharma
  • NeuroDerm
  • Adamas Therapeutics
  • Acadia
  • Sunovion
  • Roche
  • MSD
  • GSK
  • Britannia Pharmaceuticals
  • Novo Nordisk
  • Integrative Research Laboratories (IRLAB)
  • Lundbeck
  • US WorldMeds
  • Zambon
  • Eisai
  • Meiji Seika
  • Addex Therapeutics
  • Sanofi
  • Neurocrine Biosciences
  • Ono Pharmaceuticals
  • Otsuka Pharmaceutical
  • Takeda
  • Bial
  • Newron
  • Kyowa Hakko Kirin
  • Genzyme
Note: Product cover images may vary from those shown
Adroll
adroll